News Search Results
Oct 04, 2024, 21:24 ET BIOVAXYS ANNOUNCES CLOSING OF FIFTH TRANCHE OF PRIVATE PLACEMENT
antigen desensitization, and other immunological fields based on the DPX™ immune educating platform technology, developed by the former Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., which was purchased from IMV USA ("IMV") on February
More news about: BioVaxys Technology Corp.
Oct 04, 2024, 17:00 ET Spyre Therapeutics Announces Grants of Inducement Awards
Oct. 4, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy
More news about: Spyre Therapeutics, Inc.
Oct 04, 2024, 12:30 ET CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
CSL (ASX:CSL) (USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and
More news about: CSL Seqirus
Oct 04, 2024, 09:00 ET HotSpot Therapeutics to Present Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting
BOSTON, Oct. 4, 2024 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to
More news about: HotSpot Therapeutics
Oct 04, 2024, 08:30 ET Illinois Manufacturers Celebrate Manufacturing Month with Launch of "Makers on the Move" Statewide Bus Tour at Ace Sign Company in Springfield
medicines and producing healthy food, to generating energy that powers our homes and businesses,and embracing innovation through quantum computing, biotechnology and more – manufacturers are literally transforming our world." Manufacturing is the
More news about: IMEC
Oct 04, 2024, 08:05 ET Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
employees vesting over four years with a one-year cliff. About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Oct 04, 2024, 07:00 ET Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
doi:10.1200/JCO.19.02488; DESTINY-BREAST04; DESTINY-BREAST06About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
Oct 04, 2024, 03:00 ET MD Logistics to Open State-of-the-art Dedicated Pharmaceutical Warehouse in Indiana
https://kyodonewsprwire.jp/attach/202409277148-O3-2eYm0FNb.pdf *cGMP (Current Good Manufacturing Practice): regulatory standards for the manufacture and quality control of pharmaceutical and biotechnology products in the United States About the NX Group:
More news about: NIPPON EXPRESS HOLDINGS, INC.
Oct 04, 2024, 03:00 ET MD Logistics to Open State-of-the-art Dedicated Pharmaceutical Warehouse in Indiana
https://kyodonewsprwire.jp/attach/202409277148-O3-2eYm0FNb.pdf *cGMP (Current Good Manufacturing Practice): regulatory standards for the manufacture and quality control of pharmaceutical and biotechnology products in the United States About the NX Group:
More news about: NIPPON EXPRESS HOLDINGS, INC.
Oct 04, 2024, 00:30 ET Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development
subscription will be approximately HK$58.9 million. Dr. Poon's extensive experience and successful background in the biotechnology sector will help drive the Group's business development and drug R&D process, further enhancing the Group's core competitiveness. In addition,
More news about: Sirnaomics
Oct 03, 2024, 18:55 ET Enzyme-Linked Immunosorbent Assay (ELISA) Market to Grow by USD 843.9 Million (2024-2028) as AI Drives Demand for Frequent Diagnostic Testing
development enhance ELISA's sensitivity, specificity, and reduce cross reactivity. ELISA plays a crucial role in drug discovery, food safety testing, and biotechnology. Peptides, cytokines, and soluble proteins are common target substances for ELISA. ELISA's ability to measure concentration and its use in pregnancy
More news about: Technavio
Oct 03, 2024, 18:15 ET The Inner Circle acknowledges, Phillip George Hauck as a Top Pinnacle Professional
Medicine in Mount Sinai which brought the institution into compliance with the National Institutes of Health's biotechnology requirements. He notes that he also played an integral role in securing funding from the Icahn School of Medicine at Mount
More news about: The Inner Circle
Oct 03, 2024, 17:46 ET Charles Dadswell to step down as General Counsel, Illumina initiates search for successor
permanent successor. Dadswell joined the company as General Counsel in 2013, following a distinguished career providing legal counsel to the biotechnology sector. Most recently, he oversaw the company's successful challenge in the European Court of Justice of the European Commission's jurisdiction
More news about: Illumina, Inc.
Oct 03, 2024, 16:05 ET Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum
N.Y., Oct. 3, 2024 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today
More news about: Sapience Therapeutics, Inc.
Oct 03, 2024, 16:00 ET Amyris Awarded Agreement from BioMaP-Consortium to Develop Critical Medicines to Support Resilient Domestic Supply Goals
2024 /PRNewswire/ -- Amyris, a vertically integrated synthetic biology company and a leading innovator in the field of industrial biotechnology, today announced it has been awarded an agreement through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-C) for $12.3
More news about: Amyris, Inc.
Oct 03, 2024, 13:33 ET NASA Invites Media to SpaceX's 31st Resupply Launch to Space Station
[email protected]. Each resupply mission to the station delivers scientific investigations in the areas of biology and biotechnology, Earth and space science, physical sciences, and technology development and demonstrations. Cargo resupply from U.S. companies ensures a national
More news about: NASA
Oct 03, 2024, 12:00 ET LabVantage Solutions Applauded by Frost & Sullivan for Its Industry-leading Flexible, Scalable, and Cost-effective LIMS Solutions
strategic partnerships, specialized solutions, and regulatory compliance improve data security and serve various industries, including pharmaceuticals, biotechnology, food and beverage, oil and gas, forensics, academia, and the public sector. The company also offers a unique, comprehensive solution that combines
More news about: Frost & Sullivan
Oct 03, 2024, 12:00 ET LabVantage Solutions Applauded by Frost & Sullivan for Its Industry-leading Flexible, Scalable, and Cost-effective LIMS Solutions
strategic partnerships, specialized solutions, and regulatory compliance improve data security and serve various industries, including pharmaceuticals, biotechnology, food and beverage, oil and gas, forensics, academia, and the public sector. The company also offers a unique, comprehensive solution that combines
More news about: Frost & Sullivan
Oct 03, 2024, 10:45 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medpace Holdings, Inc. - MEDP
Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding. On this news, Medpace's stock price fell $35.24 per share, or 9.9%, to close at $320.58
More news about: Pomerantz LLP
Oct 03, 2024, 10:45 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medpace Holdings, Inc. - MEDP
Jefferies downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding. On this news, Medpace's stock price fell $35.24 per share, or 9.9%, to close at $320.58
More news about: Pomerantz LLP
Oct 03, 2024, 10:45 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
Jefferies downgraded Fortrea, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding. On this news, Fortrea's stock price fell $2.73 per share, or 12.29%, to close at $19.48
More news about: Pomerantz LLP
Oct 03, 2024, 10:30 ET Clinical Trial Imaging Market to Hit USD 2.07 Billion by 2029 with 7.8% CAGR | MarketsandMarkets™
2029, with a compound annual growth rate (CAGR) of 7.8%. This growth is driven by increased research and development funding in pharmaceuticals and biotechnology, coupled with a rise in Contract Research Organizations (CROs). However, high costs associated with imaging equipment and services may hinder expansion.
More news about: MarketsandMarkets
Oct 03, 2024, 10:30 ET SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Moderna, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRNA
[Click here for information about joining the class action] Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA ("mRNA") therapeutics and vaccines for the treatment of infectious diseases,
More news about: Pomerantz LLP
Oct 03, 2024, 10:30 ET SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agenus Inc. of Class Action Lawsuit and Upcoming Deadlines - AGEN
[Click here for information about joining the class action] Agenus is a clinical-stage biotechnology company that discovers and develops immuno-oncology products in the United States and internationally. Among other
More news about: Pomerantz LLP
Oct 03, 2024, 10:30 ET SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Moderna, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRNA
[Click here for information about joining the class action] Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA ("mRNA") therapeutics and vaccines for the treatment of infectious diseases,
More news about: Pomerantz LLP